Education > XRAY > Search Results

FORCE's eXaming the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

1 through 5 of 5

Relevance: Medium-High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : New PARP inhibitor veliparib showed benefit as first-line treatment for ovarian cancer

Most relevant for: Women with advanced-stage ovarian cancer

Treatment with veliparib may benefit women with advanced ovarian cancer. A recent clinical trial shows that this new PARP inhibitor may delay progression of cancer when combined with chemotherapy and when continued alone as a maintenance therapy. (8/18/20)

Read More
New PARP inhibitor veliparib showed benefit as first-line treatment for ovarian cancer

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science
View Related Clinical Trials

Update : FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer

Most relevant for: Women with advanced ovarian cancer whose tumor has a BRCA mutation or a type of tumor marker called homologous recombination deficiency (HRD)

The FDA has approved the first drug combination to be used as a first-line maintenance therapy for some women with advanced ovarian cancer. (7/7/2020)

Read More
FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer

Relevance: High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Update : New FDA approval of PARP inhibitor for maintenance therapy in ovarian cancer

Most relevant for: People with advanced ovarian cancer who have had a complete or partial response to chemotherapy

The FDA has approved the use of niraparib (Zejula) as a maintenance therapy for women with advanced ovarian cancer who have had a complete or partial response to chemotherapy. (5/7/20)

Read More
New FDA approval of PARP inhibitor for maintenance therapy in ovarian cancer

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Second surgery may not benefit women with recurrent ovarian cancer

Most relevant for: Women with recurrent ovarian cancer

Many women who have recurrent ovarian cancer have a second surgery. A new study suggests that women with platinum sensitive cancers who get chemotherapy alone may do as well as or better than women who have surgery followed by chemotherapy. (1/21/20)

Read More
Second surgery may not benefit women with recurrent ovarian cancer

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer

Most relevant for: Women newly-diagnosed with ovarian cancer

This study looked at the effectiveness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly diagnosed ovarian cancer patients who had a response to chemotherapy. (11/5/19)

Read More
Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer